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Detection of antibodies against epidermodysplasia
verruciformis-associated canine Papillomavirus 3 in sera of dogs
from Europe and Africa by enzyme-linked immunosorbent assay
Abstract
The role of Papillomaviruses (PVs) in the development of canine cancers is controversial. However,
recently a novel canine PV (CPV3) was detected in a dog affected with a condition reminiscent of
Epidermodysplasia Verruciformis (EV). The aim of the present study was to investigate into the
seroprevalence of CPV3 by using generic ELISAs for the detection of antibodies against either canine
oral papilloma virus (COPV) or CPV3. Therefore, the capsid proteins of both PV types were expressed
as GST-fusion protein antigens and adsorbed to glutathione casein-coated ELISA plates. After showing
that PV type-specific antibodies could be detected in the sera from dogs with confirmed COPV or CPV3
infection, CPV3- as well as COPV-seropositive dogs were detected in two sets of canine sera collected
in Switzerland and South Africa, respectively. We found specific antibodies against COPV as well as
against CPV3 among the tested sera and also a large number being positive for both antigens. The
seroprevalence for PV antibodies was hereby with 21.9% (COPV) and 26.9% (CPV3) among the tested
dogs from South Africa higher than among the dogs from Switzerland with 10.5% (COPV) and 1.3%
(CPV3). Our data suggest a need for further CPV-related seroepidemiological surveys in different
countries, especially in the context of clinical manifestations and possible breed predispositions. For this
purpose, the newly developed ELISAs can be a useful tool.
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The role of papillomaviruses (PVs) in the development of canine cancers is controversial. However, recently
a novel canine PV (CPV3) was detected in a dog affected with a condition reminiscent of epidermodysplasia
verruciformis (EV). The aim of the present study was to investigate the seroprevalence of CPV3 by using
generic enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies against either canine
oral PV (COPV) or CPV3. Therefore, the capsid proteins of both PV types were expressed as glutathione
S-transferase fusion protein antigens and adsorbed to glutathione-casein-coated ELISA plates. After showing
that PV type-specific antibodies could be detected in the sera from dogs with confirmed COPV or CPV3
infection, CPV3- and COPV-seropositive samples were detected in two sets of canine sera collected in Swit-
zerland and South Africa, respectively. We found specific antibodies against COPV and CPV3 among the tested
sera and also a large number that were positive for both antigens. The seroprevalences of PV antibodies of
21.9% (COPV) and 26.9% (CPV3) among the tested dogs from South Africa were higher than those among the
dogs from Switzerland at 10.5% (COPV) and 1.3% (CPV3). Our data suggest a need for further CPV-related
seroepidemiological surveys in different countries, especially in the context of clinical manifestations and
possible breed predispositions. For this purpose, the newly developed ELISAs can be a useful tool.
Papillomaviruses (PVs) are small, icosahedral, nonenvel-
oped DNA viruses with mucosal and skin tropism which are
associated with various hyperplastic, dysplastic, and neoplastic
conditions in humans and animals (21). More than 100 types of
human PVs (HPVs) have been described, and more are contin-
uously being discovered (8). The role of HPVs in the develop-
ment of human diseases, i.e., cervical carcinomas or epider-
modysplasia verruciformis (EV)-associated skin carcinomas,
is well established, and pathomechanisms have been the focus
of many studies (14, 23, 30, 35, 48). Indeed, both PCR- and
enzyme-linked immunosorbent assay (ELISA)-based tech-
niques are commonly used to carry out HPV-related epidemi-
ologic studies (2, 25).
In contrast, the role of PVs in the development of canine
cancers remains uncertain, although a clinical counterpart to
human EV has been described in dogs with PV infections (28).
Until now, only four canine PVs (CPVs) have been unambig-
uously identified and sequenced (7, 42, 43, 46). The first and
best-known CPV, canine oral PV (COPV), affects mostly ju-
venile dogs and causes warts with a typical cauliflower-like
appearance located in the oral cavity and other mucous mem-
branes (32). Since COPV-affected dogs recover spontaneously
and specific antibodies protect them from reinfection, COPV
infection is not considered a life-threatening condition (32).
Although COPV infection is endemic in most dog populations,
there never was a great demand for serological surveys,
and systematic serological data concerning the prevalence of
COPV infection are thus far unavailable. A distinct CPV, des-
ignated CPV2, was cloned only recently from a footpad lesion
of a golden retriever (46). CPV2 did not induce oral papillo-
mas in immunocompetent animals and caused a type-specific
immune response in experimentally inoculated dogs (7, 42, 43,
46). The clinical significance of CPV2 remains to be eluci-
dated. Recently, our laboratory has identified a novel CPV,
designated CPV3, and sequenced its genome. This novel CPV
was detected in lesions from a dog suffering from canine EV
and squamous cell carcinoma (42). Based on a phylogenetic
analysis, CPV3 represents the prototype of a new genus and
differs significantly from the classical COPV. Finally, an addi-
tional CPV, named CPV4, was isolated from the lesions of
several pugs suffering from numerous persisting pigmented
plaques (28, 43).
Several clinical case reports and some epidemiological evi-
dence suggest that CPVs may play a role in canine cancers (3,
4, 12, 31, 36, 38, 40, 44, 47). Due to its association with canine
EV, CPV3 was hypothesized to be a candidate agent for cer-
tain forms of canine cancers. However, data concerning the
prevalence of CPV3 in the dog population are not yet available
and serological tests and reference materials for this purpose
are lacking. Therefore, we set out to address these issues.
Typically, PVs do not readily replicate in conventional cell
cultures but serological assays can be based on heterologously
expressed viral antigens. Structural proteins L1 and L2 are
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known to assemble into the PV capsid (16). The L1 protein
forms pentameric subunits, and 72 of these subunits form one
capsid. In conventional viral particles, the L2 protein is present
only in minor amounts compared to L1. Of note, heterolo-
gously expressed L1 protein is able to form virus-like particles
(VLPs) in the absence of L2 (33). L1 is considered to be
immunodominant, and L1-based VLPs have been shown to be
highly immunogenic in the absence of L2. Therefore, L1 VLPs
have been successfully used for vaccination and as antigens in
type-specific serological assays (9, 20). Most ELISAs for HPVs
are based on the detection of L1-specific antibodies (10, 19, 24,
25, 37). It has been reported that pentameric L1 capsid sub-
units and whole VLPs may be produced equally well from
baculovirus- or Escherichia coli-based expression systems (34).
In the present study, we hypothesized that L1-GST (gluta-
thione S-transferase) fusion proteins, expressed in E. coli,
could be used as ELISA antigens in order to detect type-
specific antibodies in a collection of dog sera, which would
allow us to study the seroprevalence of CPV3 and COPV in
dogs. Indeed, our results indicate that CPV3 may be as widely
distributed in dogs as COPV in certain geographic areas.
MATERIALS AND METHODS
Plasmid construction and protein expression. COPV and CPV3 genomic
clones (42) in Bluescript vectors (Stratagene, La Jolla, CA) were used as PCR
templates. COPV and CPV3 L1 coding sequences, both truncated by 10
codons at the 5 end, were amplified by PCR with Phusion DNA polymerase
(Finzyme, Espoo, Finland). The primers designed for this purpose were
COPV L1 forward (5-GGA ATT CTT TTA CCT TCC ACC ACA GCC C-3),
COPV L1 reverse (5-GGA ATT CTT ATT TGC GTT TGC GTT TCA C-3),
CPV3 L1 forward (5-GGA ATT CCT TTT CCT GCC CCC TAA C-3), and
CPV3 L1 reverse (5-GGA ATT CTT ATT TGT TTT TTT TCC T-3). EcoRI
recognition sites included at the 5 ends of the primers were used to clone the
amplified DNA into the EcoRI site of pGEX-6P-1 (Pharmacia, Uppsala, Swe-
den). Protein expression was performed with E. coli strain BL21 as described
previously, with minor modifications (33). Instead of using a high-pressure ho-
mogenizer, we lysed the cells by passing them 10 times through a 25-gauge needle
and sonicating them.
GST capture ELISA. Polysorb 96-well plastic plates (Nunc, Roskilde, Den-
mark) were coated at 4°C overnight with 200 ng of glutathione-casein (kindly
provided by Martin Mu¨ller, DKFZ, Heidelberg, Germany) per well in 50 mM
sodium carbonate buffer, pH 9.6. After washing, the plates were incubated for 1 h
at 37°C with blocking buffer (0.2% [wt/vol] casein–0.3% [vol/vol] Tween 20 in
phosphate-buffered saline) and then incubated with the cleared lysates from E.
coli expressing GST-tagged proteins diluted in blocking buffer for 1 h at 37°C.
Sera to be tested were diluted 1:500 and incubated with a bacterial culture
equivalent of 5 l of total protein lysate of untransformed E. coli strain BL21 for
1 h at 4°C to block reactions with contaminating E. coli protein (33, 34). The
antigen-coated ELISA plates were then incubated with diluted and preincubated
sera or, for evaluation purposes, with goat anti-GST antibody (GE Healthcare,
Piscataway, NJ) diluted 1:100 in blocking buffer. After washing the plates, we
detected primary antibodies with horseradish peroxidase (HRP)-conjugated rab-
bit anti-dog immunoglobulin G (Sigma, Buchs, Switzerland) diluted 1:10,000 or
HRP-conjugated anti-goat antibody diluted 1:1,000 (Southern Biotech, Birming-
ham, AL) in blocking buffer applied for 1 h at 37°C. Plates were finally washed
six times, and substrate [78 mM acetic acid–24 mM CH3COONa  3H2O–50
mM NaH2PO4  1H2O–2 mM 2,2-azinobis(3-ethylbenzthiazolinesulfonic acid)
(ABTS; Roche, Rotkreuz, Switzerland) and 1.25 mM H2O2 applied shortly
before use] was added. After 45 min, absorbance was measured at 405 nm in a
Multiscan RC automated plate reader (Thermo Labsystems, Vantaa, Finland).
All washing steps were carried out three times with phosphate-buffered saline
containing 0.3% (vol/vol) Tween 20.
All dog sera were tested in duplicate against the antigens COPV L1-GST,
CPV3 L1-GST, and GST alone. On every 96-well plate, the same COPV- and
CPV3-positive serum was included as a positive control. The reaction of COPV
antiserum to COPV antigen served as an overall positive control, while its
reaction to CPV3 antigen served as an overall negative control. Reaction of goat
anti-GST antibody as the primary antibody and an HRP-conjugated anti-goat
secondary antibody against the antigens served as a loading control on all plates.
Six wells per plate were used as conjugate controls, which means that they were
kept in plain ELISA buffer while the other wells were incubated with primary
sera.
The coating of all of the ELISA plates used during the screening was evaluated
by testing two wells of each antigen per plate with goat anti-GST antibody as the
primary antibody and HRP-conjugated anti-goat antibody as the secondary an-
tibody.
Sera. Sera from six dogs affected by PV infections were included in the study
to serve as controls. Two of these dogs with classical COPV oral lesions, a
confirming histopathological diagnosis, and positive PCR and rolling-circle am-
plification tests were sampled at different time points. The first dog gave blood
at the initial presentation (florid clinical lesions, serum 1a) and 3 weeks later
(serum 1b). The second was also sampled at the initial presentation (serum 2a)
and 3 weeks later (no visible lesions left, serum 2b) but also 5 months after the
first presentation (serum 2c). Furthermore, three pugs with CPV4-associated
pigmented plaques (sera 3, 4, and 5) and one dog with CPV3-associated pig-
mented plaques (serum 6) were included. The presence of viral DNA in affected
tissues of these dogs was confirmed previously by PCR and rolling-circle ampli-
fication (42, 43).
Two large sets of sera were subjected to the ELISA for screening (for addi-
tional information, see Table S1 in the supplemental material). The first set,
consisting of 229 dog sera, was collected at the veterinary teaching hospital,
Vetsuisse Faculty, University of Zurich, Zurich, Switzerland, between 23 January
and 1 April 2006. The sera were taken from patients presented for various
conditions unrelated to PV infections. The second set containing 315 sera was
originally collected at three different veterinary practices in Gauteng Province,
South Africa, between May and June 2005 in order to determine the prevalence
of antibodies against canine herpesvirus in the serum of dogs older than 1 year
in breeding kennels (29). Between 3 and 20 samples from different dogs were
available from each of 36 kennels. The mean age of the Swiss dogs was 6.8  4.2
years, while the mean age of the South African dogs was 4.2  2.6 years. All of
the sera were stored at 20°C until testing.
Statistical analysis. To analyze and display the reactions of control sera,
standard box plots were constructed by using SPSS software (SPSS Schweiz AG,
Zurich, Switzerland). The correlation of loading controls was analyzed and
displayed in the form of a linear regression curve with Microsoft Excel software.
For determination of the significance of differences among differing preva-
lences, a Fisher exact test (41) was used. P values below 0.05 were classified
as significant.
RESULTS
Antigen coating. Since CPVs cannot be grown in cell cultures
for ELISA antigen production, the major capsid L1 proteins of
COPV and CPV3 were prokaryotically expressed as GST fusion
proteins. ELISA plates precoated with glutathione-casein were
used to capture these GST fusion proteins or GST alone in
separate wells of the plate. Serial dilutions of each antigen
ranging from 0.2  20 to 0.2  214 were used to identify the
antigen dilution giving equal reactions with anti-GST antibody
in all three antigen preparations as a surrogate determinant for
identical L1 amounts. Indeed, GST-containing antigen bound
to the plate provided a dose-dependent reaction upon testing
with goat anti-GST serum and an anti-goat-HRP conjugate.
The antigen concentrations corresponding to the highest com-
mon reaction were chosen for coating the ELISA plates in all
further experiments.
Preliminary characterization of reference sera. In the ab-
sence of commercially available type-specific antisera, samples
from dogs with a confirmed history (see Materials and Meth-
ods) of COPV, CPV3, or CPV4 infection were used to estab-
lish ELISAs for the detection of antibodies against COPV L1
and CPV3 L1. Serum 1a from a dog with fresh oral papillomas
yielding COPV DNA barely reacted with any of the antigens
and was therefore considered to be negative for both COPV
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and CPV3. Serum 1b, taken from the same dog 3 weeks later,
upon regression of oral warts, gave a clear reaction with the
COPV antigen but not with either the CPV3 antigen or GST.
Similarly, three consecutive serum samples from a different
dog with oral warts (sera 2a, 2b, and 2c) reacted increasingly
over time with the COPV antigen but not with CPV3 L1 or
GST. Based on case history and availability, serum 2b was used
as a preliminary positive reference serum for COPV. Simulta-
neously, due to its negative reaction against CPV3 antigen,
serum 2b served as a negative reference for this antigen. Serum
taken from a dog with a known history of CPV3 infection
(serum 6) reacted strongly with the CPV3 antigen, weakly with
the COPV antigen, and barely with GST alone. This serum was
therefore used as a positive reference serum for CPV3. Finally,
sera from three dogs with history of CPV4 infection barely
reacted with all three antigens, suggesting that these sera did
not contain substantial amounts of antibodies against either
antigen. Overall, these results indicated that our L1-GST fu-
sion proteins were able to reveal type-specific antibodies
against COPV or CPV3. Moreover, a collection of type-spe-
cific reference sera was now available for further studies.
Testing of dog sera from two geographically distinct regions.
Two available sets of dog sera were screened for antibodies
against either virus, a set of Swiss dog sera and a set of dog sera
from South Africa. As shown in Fig. 1A and B, a wide range of
reactions was detected in the two dog populations. Controls
were included for each single ELISA plate in order to better
characterize and establish the ELISA.
Analysis of antigen coating. It was important to measure
and analyze antigen coating in order to ensure comparison
of the results obtained with different ELISA plates. There-
fore, a number of wells in each plate were reserved for
reactions with an anti-GST antibody. As shown in Fig. 2, the
values measured for COPV and CPV3 in each plate were
plotted against each other and the linear regression was
determined. The regression was 0.9698, the slope of the line
was 1.0243, and the abscissa was 0.0029. The slope of nearly
1.0 and the (regression) line through the origin of the co-
ordinate system suggest that we had indeed coated the
plates with equal amounts of these two antigens and plate-
to-plate comparisons were possible.
To compensate for variations associated with plate-to-plate
differences in the final evaluation of the dog sera, the optical
density (OD) values of individual dog serum samples were
corrected by multiplication by a plate correction factor, calcu-
FIG. 1. ELISA reactions of dog sera against L1-GST fusion proteins. Panels A (CPV3 L1 antigen) and B (COPV L1 antigen) show the
reactions of 229 dog sera from Switzerland and 315 dog sera from South Africa. Each serum is represented twice, once reacting with CPV3 antigen
and once reacting with COPV antigen. In panel C, reference serum reactions are shown. On the x axis, the corrected OD values are shown (see
Materials and Methods). Sera giving high OD values are presented on the right, where the scale of the x axis is adjusted to fit all of the results.
Sera giving ODs below 0.068 (see Table 1) are in gray, and those giving ODs above 0.068 are in black. The y axis provides the number of sera with
a specific OD value.
FIG. 2. Plot of reactions (corrected OD) against adsorbed L1-GST
fusion proteins (CPV3 on the x axis, COPV on the y axis) measured on
each plate with anti-GST monoclonal antibody. Linear regression pa-
rameters: y  1.0243x  0.0029; R2  0.9698.
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lated as the ratio of the individual average plate control (mean
of six wells) to the lowest average plate control.
Analysis of reference serum performance. Duplicates of the
newly established COPV and CPV3 reference sera were
tested on all 49 of the ELISA plates used in the present
study and analyzed for reactivity against the antigens GST,
COPV L1-GST, and CPV3 L1-GST. The results are shown
as box plots in Fig. 3. Both reference sera reacted only
slightly with the GST antigen, with median OD values of
0.085 (COPV serum) and 0.099 (CPV3 serum). However,
the positive COPV reference serum reacted with a median
OD value of 0.408 against COPV antigen and with a median
OD value of 0.092 against CPV3 (Fig. 3A). The serum used
as a CPV3 positive control produced a median OD value of
0.695 with the CPV3 L1 antigen, while its reaction against
COPV produced a median OD of 0.146 (Fig. 3B).
Thus, the reference sera gave consistent results, suggest-
ing that the cutoff between a positive and a negative reaction
could be close to an OD of 0.100. Under these conditions,
the CPV3 reference serum appeared slightly positive against
the COPV antigen. Therefore, the reactions against GST
were considered the background to be subtracted to obtain
the final value. Thus, for the final analysis of the data, the
plate-corrected GST reaction ODs were subtracted from the
corresponding values obtained with the COPV and CPV3
L1 antigens.
Evaluation of cutoff values. The results of three variants to
determine cutoff values are summarized in Table 1. In variant
1, the cutoff was set equal to the highest reaction of the neg-
ative reference serum (0.0467), which deemed 84.3% of the
Swiss dog sera and 49.8% of the South African dog sera neg-
ative. In variant 2, the cutoff was set at the lowest reaction of
the positive reference serum (0.0907). Under these conditions,
92.6% of the Swiss dog sera and 78.7% of the South African
dog sera were considered negative. In variant 3, the histogram
shown in Fig. 1C was applied for the present purpose by using
a value midway between the weakest positive control reaction
and the strongest negative control reaction as the cutoff
(0.0687). Under these conditions, 89.5% of the Swiss dog sera
and 68.3% of the South African dog sera were considered
negative.
COPV and CPV3 prevalence. COPV and CPV3 seem to
circulate both in Switzerland and in South Africa. However,
the Swiss dog serum collection was not representative, which
prevents a quantitative estimation of the seroprevalence of
either COPV or CPV3 in dogs in Switzerland.
In contrast, the pool of South African dog sera was repre-
sentative for breeding dogs in Gauteng Province and included
several samples from the same premises, which allows further
interpretations. In Gauteng Province, 27 (75%) of the 36 ken-
nels harbored at least one COPV-positive animal while 32
(89%) harbored at least one CPV3-positive one. The range of
positive tested sera among the individual kennels was 0 to 57%
for COPV, with an average of 20%, in the entire pool and 0 to
67% for CPV3, with an average of 26%.
Interestingly, a very high percentage of CPV-seropositive
dogs was found to be of the Irish setter (50%) or of the
Yorkshire terrier breed (35%), whereas the bulldog breed
seemed to be underrepresented among the dogs seropositive
for COPV. To address these observations by statistical
methods, the prevalences in two representative breeds from
the Gauteng Province group with more than 20 available
samples were analyzed with Fisher’s exact test. The results
are shown in Table 2. Significant deviations in COPV prev-
alence were found for Yorkshire terriers in comparison to
the remaining population and the tested bulldogs. Thus,
FIG. 3. Standard box plots, constructed with SPSS, summarizing the reactions of reference sera against different antigens. (A) Summary of
reactions (corrected OD, y axis) of COPV reference serum measured in parallel assays against GST, CPV3 L1, and COPV L1. (B) Same assay with
CPV3 reference serum.
TABLE 1. Distribution of positive and negative reactions among
the groups with alternative cutoff values
Country (no. of
samples) and cutoff
No. (%) of samples
Negative COPVpositive
CPV3
positive
COPV  CPV3
positive
Switzerland (229)
0.0467 193 (84.3) 26 (11.4) 3 (1.3) 7 (3.0)
0.0687 205 (89.5) 21 (9.2) 0 (0.0) 3 (1.3)
0.0907 212 (92.6) 15 (6.5) 0 (0.0) 2 (0.9)
South Africa (315)
0.0467 157 (49.8) 15 (4.8) 39 (12.4) 104 (33.0)
0.0687 215 (68.3) 15 (4.8) 31 (9.8) 54 (17.1)
0.0907 248 (78.7) 14 (4.5) 24 (7.6) 29 (9.2)
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there may be a breed-specific component in the context of
CPVs.
DISCUSSION
Although CPVs apart from COPV had been postulated for
a long time, novel members of this virus family in dogs, i.e.,
CPV2, CPV3, and CPV4, have been detected and character-
ized only recently (42–46). Since oral papilloma is hardly con-
sidered a life-threatening disease, there was never a great de-
mand for serological COPV surveys of dogs and corresponding
serological data are simply not available. In contrast, some
serological data concerning CPVs have originated in the con-
text of experimental immunization (11, 39, 45, 46). Since some
of the novel CPVs, i.e., CPV3, have been detected in associa-
tion with more malignant diseases, there was a need for sero-
logical surveys, which may shed light on the prevalence of these
viruses among the dog populations of various countries.
Therefore, we set out to establish an ELISA for detecting
antibodies against two different types of CPVs, i.e., COPV, the
one about which the most is known, and CPV3, the one which
is associated with the most malignant disease. However, the
difficulties to be overcome included (i) the generation of anti-
gens from nongrowing virus, (ii) coating plates with even
amounts of antigen to allow for comparable analysis, (iii) gen-
eration and characterization of useful reference sera, (iv) anal-
ysis of dog sera and determination of useful cutoff values, and
(v) interpretation of data with regard to the prevalence of the
viruses of interest.
Difficulties i and ii. The antigen used in our ELISA was
prepared from heterologously expressed CPV capsid protein
L1 N terminally fused to GST. This method is frequently used
to generate ELISA antigens since the subsequent purification
steps are well established (13, 17, 22, 33, 34). Others have
shown that GST-tagged L1 proteins spontaneously form pen-
tamers and VLPs (5), and it has been reported that this capture
technique equals in its results the alternative system of baculo-
virus-expressed VLPs (33). Indeed, type-specific results were
obtained throughout our work, which implies that the antigen
preparations were adequate for the present purpose.
The N-terminal GST tag of the ELISA antigens was not only
used for binding of the antigen to the ELISA plate and simul-
taneous antigen purification but also served as an epitope to
measure the amount of bound antigen per well with anti-GST
antibodies. Although it is technically not feasible to coat each
single well with essentially the same amount of antigen, control
measures on each plate provided confidence that comparable
amounts of the two different L1 antigens were being used for
analysis of the dog sera (Fig. 2). Thus, a comparison between
reactions against the different fusion proteins was reasonable.
Difficulty iii. According to the reactions of our reference
sera, the newly developed ELISAs were able to discriminate
between dogs that had recently undergone COPV and CPV3
infections, respectively, whereas sera from dogs with CPV4
infections did not react against either COPV L1 or CPV3 L1.
These results provided confidence that the ELISA was able to
discriminate specific reactions against the two virus types.
Therefore, also the newly characterized reference sera were
considered type specific. However, CPV3 represents a novel
virus and cross-reactivity to any known or unknown PV has to
be kept in mind as a possibility. Yet, based on similar experi-
ments, others have concluded that COPV and CPV2 are sero-
logically distinct (46).
Difficulty iv. Despite the confidence of having established
valuable tools for seroepidemiological studies regarding
COPV and CPV3, defining widely acceptable cutoff values
remained a challenge that could not unambiguously be solved
at the present state of knowledge. Therefore, we decided to
analyze the reactions of two different sets of dog sera against
COPV L1 and CPV3 L1. The results (Fig. 1) show that a
certain number of sera within each set overlapped with the
reactions of the negative reference serum, whereas a multitude
of sera reacted clearly more strongly than the negative sera.
These observations support the conclusion that some of these
sera reacted specifically against one or both of the L1 proteins
whereas other sera reacted negatively.
A simple method to set a cutoff value is to define the highest
negative control reaction as the cutoff and consider all higher
reactions positive. This choice results in relatively high sensi-
tivity at the cost of specificity. An analogous method with the
lowest positive reaction as the cutoff leads to higher specificity
at the cost of sensitivity. In contrast to the situation in the dog,
ELISAs for detection of antibodies against human PVs are
frequently used and several methods to define cutoff values
have been suggested. Three of those were also tested in the
present work, since they have been subjected to comparative
analysis (19). In our case, histogram analysis (variant 3 in our
results) seemed to be the most preferable of the methods
tested because of its feasibility, simplicity, and balancing influ-
ence on specificity and sensitivity.
Difficulty v. One set of tested sera was obtained from ran-
domly chosen canine patients of a veterinary teaching hospital
in Switzerland and is therefore not quantitatively representa-
tive of the Swiss dog population. One may conclude, however,
that not only COPV but also CPV3 is prevalent in Switzerland.
This was not overly surprising, since CPV3 was first detected in
Switzerland (42). However, conclusions about the prevalence
of CPV3-infected dogs were not possible and further studies in
various countries should be done to address this issue.
In contrast, the second set, comprising 315 sera from 36
kennels, consisted of a representative sample of breeding dogs
in the South African province of Gauteng. Almost the same set
had previously been used for determining the seroprevalence
of canine herpesvirus 1 in Gauteng Province (29). In that study,
canine herpesvirus 1-positive dogs were found in 45% of the
kennels and the prevalence of seropositive dogs in affected
kennels was close to 40%. Interestingly, both COPV (75%
of kennels) and CPV3 (89% of kennels) seem to be even more
prevalent in the same population. In this context, it has to be
considered that little is known concerning the duration of se-
ropositivity against various CPVs.
As shown in Table 1, the number of individual CPV-positive
dog sera from the Gauteng Province set ranged from 25 to
50%, depending on the cutoff value applied. The largest frac-
tion of the positive sera (10 to 30%) reacted against both
COPV L1 and CPV3 L1. These dogs could have had contact
with both viruses, might have developed antibodies against
viruses closely related to COPV and/or CPV3, or could have
cross-reacting antibodies in their serum. Our study does not
allow us to completely rule out such possibilities, but surveys of
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humans have demonstrated that coinfections with more than
one PV are very common (15, 25).
It was tempting to analyze our data for statistically signifi-
cant correlations between antibodies against CPVs and factors
such as dog breed, age, gender, and kennel size. For example,
as indicated in Table 2, the Yorkshire terrier was found to be
significantly overrepresented among the COPV-positive dogs
tested. These tested Yorkshire terriers, however, originated
from only three kennels with differing prevalences, and thus,
possible cohort effects have to be kept in mind (18, 27). The
observations nevertheless indicate that breed disposition may
actually play a role in the prevalence of various CPVs. Indeed,
reports strongly suggest that genetic predisposition should be
considered in the context of PV-associated diseases (1, 6, 26,
43). However, our serum pools were not designed to warrant
extensive stratification of the data. Therefore, we provide ad-
ditional data for potential analyses only as supplemental ma-
terial. For an overview of the breed distribution of the animals
in the two sets analyzed, see Table S1 in the supplemental
material, and for the distribution of positive tested sera from
the perspective of age and gender, see Fig. S2 in the supple-
mental material. For the number of CPV-seropositive dogs in
relation to the individual kennel sizes, see Table S3 in the
supplemental material. We consider their presentation impor-
tant in view of further analyses of these aspects. More studies
in this direction are certainly warranted.
In summary, our work provides the first insight into the
seroprevalence of CPV3. Serological reactors against this
novel PV were detected on two continents. Our data suggest
that there is a need for further seroepidemiological surveys in
different countries and clinical studies related to the potential
diseases caused by CPV3. With the newly developed diagnostic
tools at hand, such studies will be feasible.
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